Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03141125
Other study ID # UI-PAL/CCD-SSc.2016
Secondary ID
Status Completed
Phase N/A
First received June 20, 2016
Last updated August 27, 2017
Start date January 2016
Est. completion date August 2017

Study information

Verified date August 2017
Source Indonesia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study about the effect of ethanol extract physalis angulate in scleroderma patients with standard therapy to reduce skin fibrosis based on modified Rodnan Skin Score, reduce inflammation, immunological response and fibrosis: A Randomized Clinical Placebo ControlledTrial with a prospective cohort study on scleroderma outpatient clinic in Cipto Mangunkusumo Hospital in Jakarta and Hasan Sadikin Hospital in Bandung, from January 2016 to July 2017


Description:

Background.

Scleroderma is a systemic autoimmune disease that can not be cured, the progression of the disease still difficult to prevent and lead to increased morbidity and mortality. Disease-modifying anti-rheumatic drugs (DMARDs) as standard immunosuppressant drugs to reduce, eliminate, inhibit inflammation and fibrosis in scleroderma patient is still less effective.

Objectives.

To evaluate the effect of ethanol extract of Physalis angulate Linn to reduce skin fibrosis based on MRSS, ESR, BAFF, sCD40L, and P1NP in scleroderma patients with standard therapy

Methods.

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on scleroderma patients with standard therapy, who admitted to Cipto Mangunkusumo Hospital Jakarta and Hasan Sadikin Hospital Bandung, from January 2016 to July 2017.

Patients must be controlled every month until three months for follow up. Subjects were divided into two parallel group, one of intervention group, and one of placebo group


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date August 2017
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

1. Patients who meet the criteria of the type of limited scleroderma diagnosis / limited or diffuse type.

2. Patients who routine control in rheumatology outpatient clinics in Ciptomangunkusumo hospital Jakarta and Hasan Sadikin hospital Bandung RSHS who received standard therapy for scleroderma with a stable dose over the past 3 months.

3. The research subjects aged 15 to 60 years.

4. Subjects with modified Rodnan Skin score = 5.

5. Disease duration = 1 year

Exclusion Criteria:

1. Impaired liver function with cirrhosis

2. Chronic Renal dysfunction (chronic kidney disease stages 4-5). Or creatinine levels> 2 mg / dL in the last 1 month prior to randomization.

3. Other autoimmune disease/overlap syndrome.

4. Received a steroid/prednisone >10 mg/day in the last 1 month.

5. Patients who are pregnant or breastfeeding.

6. Patients with active tuberculosis and or are being treated with anti-tuberculosis medicines.

7. Severe heart disease. (Heart Disease with impaired function according to the New York Heart Association Class III or IV)

8. History of allergies to herbal Ciplukan / Physalis angulate Linn. or a history of hypersensitivity to certain drugs.

9. Hypotension (BP <90/60 mmHg)

10. Hypoglycemia (Glucose level <70 mg / dL)

11. Do not want to participate in the study

Study Design


Intervention

Other:
Physalis angulata ethanol extract
Ethanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months
Placebo
No active component at the same dosage of 3x250 mg/day given orally for 3 months

Locations

Country Name City State
Indonesia Hasan Sadikin Hospital Bandung West Java
Indonesia Ciptomangunkusumo Hospital Jakarta

Sponsors (2)

Lead Sponsor Collaborator
Indonesia University Netherlands: Ministry of Health, Welfare and Sports

Country where clinical trial is conducted

Indonesia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Degree of skin fibrosis based on modified Rodnan Skin Score (mRSS) Clinical improvement of skin fibrosis in scleroderma patients measured by modified Improvement in skin fibrosis is defined if there is a significant reduced of mRSS. 3 months of intervention
Secondary Level of P1NP serum Improvement is defined if there is a significant reduced of P1NP serum level 3 months of intervention
Secondary Value of ESR Improvement is defined if there is a significant reduced of ESR value 3 months of intervention
Secondary Level of BAFF serum Improvement is defined if there is a significant reduced of BAFF serum level 3 months of intervention
Secondary Level of sCD40L serum Improvement is defined if there is a significant reduced of sCD40L serum level. 3 months of intervention
See also
  Status Clinical Trial Phase
Completed NCT02798055 - Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
Completed NCT01959815 - Novel Screening Strategies for Scleroderma PAH
Completed NCT03274076 - Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Phase 1/Phase 2
Completed NCT02915835 - Riociguat in Scleroderma Associated Digital Ulcers Phase 2
Active, not recruiting NCT01895244 - Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis Phase 2
Completed NCT00930683 - A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma Phase 1
Completed NCT00883129 - Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) Phase 2
Completed NCT00074568 - Scleroderma Registry
Recruiting NCT04797286 - Sildenafil for Early Pulmonary Vascular Disease in Scleroderma Phase 2
Completed NCT03222492 - Brentuximab Vedotin for Systemic Sclerosis Phase 1/Phase 2
Completed NCT03207997 - MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients N/A
Recruiting NCT04464434 - Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis Phase 4
Recruiting NCT04246528 - SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF) N/A
Completed NCT05080738 - Upper Extremity Home Exercises in Patients With Scleroderma N/A
Recruiting NCT03726398 - CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH Phase 2/Phase 3
Recruiting NCT05085444 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma Early Phase 1
Completed NCT02062125 - Calcinosis in a Single-Center Scleroderma Population
Completed NCT04588714 - Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention N/A
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT02835196 - Optical Elastography of Systemic Sclerosis Skin